Results 131 to 140 of about 32,298 (248)

From hepatic to hematopoietic: LRH‐1's expanding cellular repertoire to the immune system

The FEBS Journal, EarlyView.
The nuclear receptor LRH‐1 is a well‐characterized regulator of endodermal tissue. Yet, increasing evidence indicates that LRH‐1, although expressed at low levels, is also a critical regulator of the hematopoietic system. LRH‐1 regulates the immune system by contributing to immune cell‐specific functions.
Lukas Meisinger, Alice Wiedmann, Rayan Hassan M. Elshikhidriss, Thomas Brunner   +3 more
wiley   +1 more source

Navigating market access after conditional reimbursement: a communication roadmap for disinvesting orphan drugs. [PDF]

Int J Technol Assess Health Care
Abdallah K, Blonda A, Godman B, Huys I, Claes K, Denier Y, Simoens S.   +6 more
europepmc   +1 more source

CD36‐mediated lipid rewiring in the metabolic adaptation of tumour ecosystems

The FEBS Journal, EarlyView.
Nutrient deprivation drives a lipid‐centric shift in tumour metabolic symbiosis and signalling network. CD36 functions as a bidirectional bridge, transferring fatty acids from stromal donors (adipocytes, CAFs) to the ecosystem tumour‐ and microenvironment‐dependently.
Anna Sebestyén, Viktória Varga, Fatime Szalai, Risa Miyaura, Nóra Förhécz, Bálint Csikós, Rebeka Gelencsér, Zsófia Gábriel, Timea Komlódi, Katalin Dezső, Ildikó Krencz, Dorottya Moldvai   +11 more
wiley   +1 more source

Societal participation in the development of orphan drugs: a systematic review. [PDF]

Front Med (Lausanne)
Akodad S, De Smedt D, Stevens H.
europepmc   +1 more source

Real‐World Outcomes of Prophylaxis With rIX‐FP in Germany: A Prospective, Non‐Interventional Study in Haemophilia B

Haemophilia, EarlyView.
ABSTRACT Introduction Efficacy and safety of albutrepenonacog alfa (rIX‐FP) in people with haemophilia B (PwHB) has been previously demonstrated in clinical trials. However, real‐world data insights are required. Aim To describe real‐world effectiveness and tolerability of rIX‐FP in PwHB in Germany.
Johannes Oldenburg, Swee Wenning, Susanne Holzhauer, Wolfgang Miesbach, Robert Klamroth, Thomas Linhoff, Patrick Sommerer, Christian Pfrepper, Martin Olivieri, all study investigators   +9 more
wiley   +1 more source

Drug lag and associated factors of orphan drugs approved by the U.S. in China. [PDF]

Front Pharmacol
Mo Q, He J, Guo Q, Yang Y.
europepmc   +1 more source

Can the Development of Orphan Drugs Include Wider Patient Engagement? A Citizens' Jury to Explore a Promissory Notion. [PDF]

Health Expect
Frost J, Widening Engagement Patient Advisory Group, Mandizha J, van den Dungen C, Asare L, Pope C.   +5 more
europepmc   +1 more source

Current status and trend of clinical development of orphan drugs in China. [PDF]

Orphanet J Rare Dis, 2022
Xiang Z, Jiang W, Yan B, Jiang J, Zheng H.   +4 more
europepmc   +1 more source

Next Generation Smart Implant Surfaces: Engineering Multifunctional Antimicrobial, Immunomodulatory and Regenerative Interfaces

Journal of Periodontal Research, EarlyView.
Natural‐inspired nano‐textured implant surfaces can be functionalised to modulate macrophage polarisation and local immune responses. This bioactive control promotes improved tissue integration and healing outcomes. ABSTRACT Dental implants rely on a stable and functional interface between the implant surface, surrounding tissues, and the oral ...
Roberto S. Pessoa, Lauren E. Steele, Mehvish Mumtaz, Denver P. Linklater, Neil M. O'Brien‐Simpson, Vladimir Baulin, Peter Kingshott, Roy Judge, Alastair J. Sloan, Elena P. Ivanova   +9 more
wiley   +1 more source

Methodological challenges in Dutch HTA of non-oncological orphan drugs: a retrospective analysis and price comparison using different pricing models. [PDF]

Orphanet J Rare Dis
Walraven J, Kaveh M, Uyl-de Groot C.
europepmc   +1 more source